Hemp-Derived Extracellular Vesicles: A Novel Frontier in Nanomedicine and Therapeutics.
| Journal | BioDrugs: clinical immunotherapeutics, biopharmaceuticals and gene therapy |
| Study Type | Clinical Study |
| Population | Human participants |
This item covers developments relevant to cannabis medicine and clinical practice. Clinicians monitoring evidence in this area should review the source material.
While mammalian-derived extracellular vesicles (EVs) face significant challenges in clinical translation due to scalability, cost, and safety, plant-derived EVs (PDEVs) have emerged as a promising alternative. This review focuses on EVs derived from hemp (Cannabis sativa L.), or HEVs, a particularly compelling source that combines the general benefits of PDEVs, such as improved safety and scalability, with a unique, inherent therapeutic cargo. HEVs are naturally enriched with a potent mix of cannabinoids, terpenes, and flavonoids, which may enhance therapeutic outcomes through synergistic interactions-a phenomenon known as the ‘entourage effect.’ Preclinical studies already demonstrate their potential, showing significant anti-cancer effects against aggressive tumors like glioblastoma, along with neuroprotective and anti-inflammatory properties. However, the critical challenge hindering their clinical application is the lack of standardized, GMP (Good Manufacturing Practice)-compliant
“This is a development worth tracking. The clinical implications will become clearer as more evidence accumulates.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
What exactly are hemp-derived extracellular vesicles, or HEVs?
They are extracellular vesicles, or EVs, derived from hemp (Cannabis sativa L.), which the review calls HEVs. They belong to the broader group of plant-derived EVs, and the review describes hemp as a particularly compelling source because it combines the general benefits of plant EVs with a unique, inherent therapeutic cargo.
Why use plant vesicles instead of vesicles from mammalian cells?
Mammalian-derived extracellular vesicles face significant challenges in clinical translation related to scalability, cost and safety. Plant-derived vesicles have emerged as a promising alternative, and the review credits them with general benefits such as improved safety and scalability.
What compounds do hemp vesicles carry, and why might that matter?
Hemp vesicles are naturally enriched with a potent mix of cannabinoids, terpenes and flavonoids. The review suggests these compounds may enhance therapeutic outcomes through synergistic interactions, a phenomenon known as the entourage effect. This is presented as a possibility rather than a proven benefit.
What has preclinical research shown about hemp vesicles so far?
According to the review, preclinical studies show significant anti-cancer effects against aggressive tumors such as glioblastoma, along with neuroprotective and anti-inflammatory properties. These are preclinical findings that demonstrate potential, not results from treating patients.
What is holding back hemp vesicles from clinical use?
The review identifies the critical challenge as a lack of standardization and of compliance with Good Manufacturing Practice (GMP). Until that gap is addressed, the promising preclinical findings on hemp vesicles face a key barrier to clinical application.
